A myriad of AI, science, and technology experts explore the real challenges and enormous opportunities facing entrepreneurs who are building the future of health. Raising Health, a podcast by a16z Bio + Health and hosted by Kris Tatiossian and Olivia Webb, dives deep into the heart of biotechnology and healthcare innovation. Join veteran company builders, operators, and investors Vijay Pande, Julie Yoo, Vineeta Agarwala, and Jorge Conde, along with distinguished guests like Mark Cuban, Greg ...
…
continue reading
Content provided by HCPLive Podcasts. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by HCPLive Podcasts or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
HCPLive Under 5 Audio Recap: Week of 03/16
MP3•Episode home
Manage episode 473971827 series 3310601
Content provided by HCPLive Podcasts. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by HCPLive Podcasts or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!
Interested in a more traditional, text rundown? Check out the HCPFive!
Top 5 Healthcare Headlines for March 23-30, 2025:
Zetomipzomib Shows Promise for Autoimmune Hepatitis in Phase 2a PORTOLA Trial
Zetomipzomib demonstrated steroid-sparing biochemical remissions in refractory autoimmune hepatitis patients, aligning with AASLD treatment guidelines in the Phase 2a PORTOLA trial.
Solriamfetol Significantly Reduces ADHD Symptoms in Axsome’s Phase 3 Trial
Solriamfetol met its primary endpoint in the Phase 3 FOCUS trial, significantly improving ADHD symptoms, with a higher proportion of patients achieving clinical response compared to placebo.
Sozinibercept for Wet AMD Misses Primary Endpoint in Phase 3 COAST Trial
Sozinibercept combined with aflibercept failed to meet the primary endpoint for visual acuity improvement in wet AMD, showing no added benefit over aflibercept monotherapy.
FDA Approves Gepotidacin (Blujepa) for Uncomplicated UTI
The FDA approved gepotidacin for uncomplicated urinary tract infections based on Phase 3 trials demonstrating non-inferiority to nitrofurantoin in female adults and adolescents.
FDA Issues CRL for Etripamil Nasal Spray (Cardamyst) in PSVT
The FDA issued a Complete Response Letter for etripamil nasal spray, citing manufacturing and control issues while confirming no concerns regarding its clinical safety or efficacy.
Interested in a more traditional, text rundown? Check out the HCPFive!
Top 5 Healthcare Headlines for March 23-30, 2025:
Zetomipzomib Shows Promise for Autoimmune Hepatitis in Phase 2a PORTOLA Trial
Zetomipzomib demonstrated steroid-sparing biochemical remissions in refractory autoimmune hepatitis patients, aligning with AASLD treatment guidelines in the Phase 2a PORTOLA trial.
Solriamfetol Significantly Reduces ADHD Symptoms in Axsome’s Phase 3 Trial
Solriamfetol met its primary endpoint in the Phase 3 FOCUS trial, significantly improving ADHD symptoms, with a higher proportion of patients achieving clinical response compared to placebo.
Sozinibercept for Wet AMD Misses Primary Endpoint in Phase 3 COAST Trial
Sozinibercept combined with aflibercept failed to meet the primary endpoint for visual acuity improvement in wet AMD, showing no added benefit over aflibercept monotherapy.
FDA Approves Gepotidacin (Blujepa) for Uncomplicated UTI
The FDA approved gepotidacin for uncomplicated urinary tract infections based on Phase 3 trials demonstrating non-inferiority to nitrofurantoin in female adults and adolescents.
FDA Issues CRL for Etripamil Nasal Spray (Cardamyst) in PSVT
The FDA issued a Complete Response Letter for etripamil nasal spray, citing manufacturing and control issues while confirming no concerns regarding its clinical safety or efficacy.
190 episodes
MP3•Episode home
Manage episode 473971827 series 3310601
Content provided by HCPLive Podcasts. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by HCPLive Podcasts or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!
Interested in a more traditional, text rundown? Check out the HCPFive!
Top 5 Healthcare Headlines for March 23-30, 2025:
Zetomipzomib Shows Promise for Autoimmune Hepatitis in Phase 2a PORTOLA Trial
Zetomipzomib demonstrated steroid-sparing biochemical remissions in refractory autoimmune hepatitis patients, aligning with AASLD treatment guidelines in the Phase 2a PORTOLA trial.
Solriamfetol Significantly Reduces ADHD Symptoms in Axsome’s Phase 3 Trial
Solriamfetol met its primary endpoint in the Phase 3 FOCUS trial, significantly improving ADHD symptoms, with a higher proportion of patients achieving clinical response compared to placebo.
Sozinibercept for Wet AMD Misses Primary Endpoint in Phase 3 COAST Trial
Sozinibercept combined with aflibercept failed to meet the primary endpoint for visual acuity improvement in wet AMD, showing no added benefit over aflibercept monotherapy.
FDA Approves Gepotidacin (Blujepa) for Uncomplicated UTI
The FDA approved gepotidacin for uncomplicated urinary tract infections based on Phase 3 trials demonstrating non-inferiority to nitrofurantoin in female adults and adolescents.
FDA Issues CRL for Etripamil Nasal Spray (Cardamyst) in PSVT
The FDA issued a Complete Response Letter for etripamil nasal spray, citing manufacturing and control issues while confirming no concerns regarding its clinical safety or efficacy.
Interested in a more traditional, text rundown? Check out the HCPFive!
Top 5 Healthcare Headlines for March 23-30, 2025:
Zetomipzomib Shows Promise for Autoimmune Hepatitis in Phase 2a PORTOLA Trial
Zetomipzomib demonstrated steroid-sparing biochemical remissions in refractory autoimmune hepatitis patients, aligning with AASLD treatment guidelines in the Phase 2a PORTOLA trial.
Solriamfetol Significantly Reduces ADHD Symptoms in Axsome’s Phase 3 Trial
Solriamfetol met its primary endpoint in the Phase 3 FOCUS trial, significantly improving ADHD symptoms, with a higher proportion of patients achieving clinical response compared to placebo.
Sozinibercept for Wet AMD Misses Primary Endpoint in Phase 3 COAST Trial
Sozinibercept combined with aflibercept failed to meet the primary endpoint for visual acuity improvement in wet AMD, showing no added benefit over aflibercept monotherapy.
FDA Approves Gepotidacin (Blujepa) for Uncomplicated UTI
The FDA approved gepotidacin for uncomplicated urinary tract infections based on Phase 3 trials demonstrating non-inferiority to nitrofurantoin in female adults and adolescents.
FDA Issues CRL for Etripamil Nasal Spray (Cardamyst) in PSVT
The FDA issued a Complete Response Letter for etripamil nasal spray, citing manufacturing and control issues while confirming no concerns regarding its clinical safety or efficacy.
190 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.